Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Paramethadione. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 3/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | CTSG | P08311 | 1/20 | 0.30 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Paramethadione SCHEMBL23832172 | 0.92 | LMNA (0.70) | LMNAPGRELANECTSGPRTN3 | |
| SCHEMBL1363134 | 0.81 | LMNA (0.54) | LMNA | |
| SCHEMBL8363739 | 0.76 | LMNA (0.52) | LMNAATMPGRTSHRCYP2C19 | |
| Trimethadione SCHEMBL28882 | 0.72 | LMNA (1.00) | LMNAPGRELANECTSGPRTN3 | |
| SCHEMBL13581345 | 0.70 | LMNA (0.42) | LMNAELANECTSGPRTN3 | |
| SCHEMBL13581344 | 0.70 | LMNA (0.42) | LMNAELANECTSGPRTN3 | |
| SCHEMBL1362309 | 0.68 | LMNA (0.60) | LMNA | |
| Ethadione SCHEMBL13724326 | 0.68 | LMNA (0.70) | LMNAPGRELANECTSGPRTN3 | |
| SCHEMBL887992 | 0.68 | — | — | |
| Metharbital SCHEMBL4885996 | 0.66 | LMNA (0.59) | LMNAATMELANECTSGPRTN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1211124-C | Thixotropic formulations for filling hard capsules | PF MEDICAMENT (FR) | 2005-07-20 | — | — | CN | claimed |
| CN-1308522-A | Thixotropic formulations for filling hard capsules | PF MEDICAMENT (FR) | 2001-08-15 | — | — | CN | claimed |
| US-20260021178-A1 | BCMA-TARGETING AGENT, AND COMBINATION THERAPY WITH A GAMMA SECRETASE INHIBITOR | NOVARTIS AG (CH) | 2026-01-22 | — | — | US | disclosed |
| US-20250236671-A1 | CD229 Car T Cells And Methods Of Use Thereof | UNIV UTAH RES FOUND (US) | 2025-07-24 | — | — | US | disclosed |
| US-20240352123-A1 | HIGH SELECTIVE CD229 ANTIGEN BINDING DOMAINS AND METHODS OF USE | UNIV UTAH RES FOUND (US) | 2024-10-24 | — | — | US | disclosed |
| EP-4441085-A2 | HIGH SELECTIVE CD229 ANTIGEN BINDING DOMAINS AND METHODS OF USE | University of Utah Research Foundation (US) | 2024-10-09 | — | — | EP | disclosed |
| US-11952428-B2 | BCMA chimeric antigen receptors and uses thereof | NOVARTIS AG (CH) | 2024-04-09 | — | — | US | disclosed |
| US-11939389-B2 | BCMA chimeric antigen receptors and uses thereof | NOVARTIS AG (CH) | 2024-03-26 | — | — | US | disclosed |
| US-20230416390-A1 | BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-12-28 | — | — | US | disclosed |
| US-20230250179-A1 | BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230183368-A1 | BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-06-15 | — | — | US | disclosed |
| CN-1211124-C | Thixotropic formulations for filling hard capsules | PF MEDICAMENT (FR) | 2005-07-20 | — | — | CN | disclosed |
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | CEDARS-SINAI MEDICAL CENTER | 2005-04-28 | — | — | US | disclosed |
| WO-2005025511-A2 | POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER | CEDARS-SINAI MEDICAL CENTER (US) | 2005-03-24 | — | — | WO | disclosed |
| CN-1515244-A | Protein-stable pharmacological active matter, its preparation and application method | �Ϻ���ͨ��ѧ | 2004-07-28 | — | — | CN | disclosed |
| CN-1515246-A | New preparation of medicine, its preparation and application method | �Ϻ���ͨ��ѧ | 2004-07-28 | — | — | CN | disclosed |
| CN-1157185-C | Protein-stabilized pharmacologically active agents and methods for their preparation and use | �Ϻ���ͨ��ѧ | 2004-07-14 | — | — | CN | disclosed |
| CN-1308522-A | Thixotropic formulations for filling hard capsules | PF MEDICAMENT (FR) | 2001-08-15 | — | — | CN | disclosed |
| CN-1267214-A | Novel preparation of medicament and preparation and application method thereof | VIVORX PHARMACEUTICALS INC (US) | 2000-09-20 | — | — | CN | disclosed |
| EP-0592366-A1 | Photochromic compounds, their preparation and their use | CIBA-GEIGY AG (CH) | 1994-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416390-A1 | BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | TNFRSF9, CD40, BCR | LMNA 4261/4885ATM 3604/4885PGR 2262/4885 |
| US-11939389-B2 | BCMA chimeric antigen receptors and uses thereof | TNFRSF9, CD40, BCR | LMNA 4261/4885ATM 3604/4885PGR 2262/4885 |
| US-11952428-B2 | BCMA chimeric antigen receptors and uses thereof | TNFRSF9, CD40, BCR | LMNA 4261/4885ATM 3604/4885PGR 2262/4885 |
| US-20250236671-A1 | CD229 Car T Cells And Methods Of Use Thereof | CD2, CD2BP2, CD22 | LMNA 3833/4885ATM 1433/4885PGR 4063/4885 |
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | KCNN2, KCNN1, KCNN3 | LMNA 541/4885ATM 2959/4885PGR 1349/4885 |
| US-20260021178-A1 | BCMA-TARGETING AGENT, AND COMBINATION THERAPY WITH A GAMMA SECRETASE INHIBITOR | GSAP, BACE1, CD79B | LMNA 1575/4885ATM 1793/4885PGR 696/4885 |
| US-20230250179-A1 | BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | TNFRSF9, CD40, BCR | LMNA 4261/4885ATM 3604/4885PGR 2262/4885 |
| US-20230183368-A1 | BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | TNFRSF9, CD40, BCR | LMNA 4261/4885ATM 3604/4885PGR 2262/4885 |
| US-20240352123-A1 | HIGH SELECTIVE CD229 ANTIGEN BINDING DOMAINS AND METHODS OF USE | CD2BP2, CD2, CD22 | LMNA 4496/4885ATM 2264/4885PGR 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.